NOTCH1
Ayala Pharmaceuticals to Raise $25 Million in Private Financing
The company will use the funding to begin a Phase II/III clinical trial of its gamma secretase inhibitor, AL102, in desmoid tumors this year.
Ayala Pharmaceuticals Doses First Notch-Activated TNBC Patient in Phase II Study of AL101
The trial will evaluate triple-negative breast cancer patients' responses to Ayala's gamma secretase inhibitor AL101 in the Tenacity trial.
NOTCH Mutations Potentially Predictive for Immunotherapy Response in Lung Cancer
Deleterious NOTCH mutations may predict more favorable immune checkpoint responses in lung cancer patients without EGFR or ALK mutations.
ESMO 2019 Precision Oncology Highlights
A collection of biomarker- and genomic testing-driven precision oncology research presented at the European Society of Medical Oncology Congress.
Ayala, ArcherDx Partner to Advance CDx for Notch Inhibitors
The partners are working together to advance tests that will identify which cancer patients have Notch activating mutations and fusions.